|8:30 a.m.||Registration and Poster Setup|
|9:00 a.m.||Opening Remarks|
|9:10 a.m.||Keynote 1: Dr. Shu Chien|
|10:10 a.m.||Panel 1: Academic Career Development|
|11:10 a.m.||Coffee Break|
|11:30 a.m.||Elevator Talk|
|12:00 p.m.||Poster and Lunch|
|2:00 p.m.||Panel 2: R&D Jobs in Industry|
|3:00 p.m.||Keynote 2: Dr. Michael Chang|
|4:00 p.m.||Coffee Break|
|4:30 p.m.||Panel 3: Beyond The Bench|
|Closing Remarks & Poster Award Ceremony|
Professor Shu Chien is University Professor at the University of California San Diego, with research focuses on molecular, cellular and integrative bioengineering. He has served in leadership position in many professional organizations, including Federation of American Societies of Experimental Biology and American Institute for Medical and Biological Engineering. He is a member of National Academy of Sciences, National Academy of Engineering, National Academy of Medicine, and American Academy of Arts and Sciences, as well as Chinese Academy of Sciences and Academia Sinica. He has received many awards and medals, including the Presidential Prize in life sciences in Taiwan, ROC, and the National Medal of Science, the highest honor for scientists and engineers in USA, bestowed by President Obama.
For now, please visit here
Details coming soon!
Dr. Michael Chang is the world's top chemist and entrepreneur. He found five pharmaceutical companies in U.S. and Taiwan and raised more than $1 billion. He served as President and Chief Executive Officer at Optimer Pharmaceuticals, Inc. from 1998 to 2009. From 1998 to 2000, Dr. Chang was the Chief Scientific Officer of Nu Skin Enterprises, Inc. In 1995, Dr. Chang co-founded Pharmanex, Inc., a natural healthcare company, where he was employed as Senior Vice President, Research and Development and Chief Science Officer. Before Pharmanex, Dr. Chang worked for 15 years in the pharmaceutical industry, at Merck & Co, Inc., Rhone-Poulenc Rorer Inc., and ArQule, Inc. In 2002, he brought his extensive experience back to Taiwan and found OBI Pharma, Inc. (台灣浩鼎) focusing on the immunotherapy in cancer and infectious diseases. Now the OBI Parma is the most valuable biotech company. His devotion lights up the future of biotechnology in the Taiwan.
Dr. Hsieh received his B.S. degree from the National Taiwan University in 1982 and an M.S. degree from National Yang-Ming Medical College in Taipei, Taiwan. He received his Ph.D. in 1989 from the University of Wisconsin at Madison. Dr. Hsieh then did a post-doctoral fellowship at MD Anderson Cancer Center. Dr. Hsieh is now John McConnell Distinguished Chair Professor in Prostate Cancer Research and the Director of the Jean H. and John T. Walter, Jr., Center for Research in Urologic Oncology at UT Southwestern. He has received several awards including: the Gillson Longenbaugh Research Award; SBUR/Merck Young Investigator Award. These interests include: signaling pathways leading to cancer metastasis; develop of novel treatment strategies of advanced prostate cancer; and non-invasive molecular imaging.
Jen Liou received her Bachelor and Master of Science degrees in Zoology from National Taiwan University, and her Ph.D. in Immunology from the University of California at San Francisco (UCSF) under the guidance of Arthur Weiss. She did her postdoctoral training with Tobias Meyer at Stanford University where she did the breakthrough work on STIM1 and cell signaling by pioneering the development of a human siRNA library. She received an Endowed Scholar Award and joined UT Southwestern Medical Center as a faculty in 2009. Her research group aims to elucidate the molecular basis of inter-organelle signaling using synthetic biology, chemical genetics and cutting-edge live-cell imaging techniques.
J. Jack Lee is professor of biostatistics, Kenedy Foundation Chair in Cancer Research, and Associate Vice Provost in Quantitative Research at MD Anderson. Dr. Lee received his dental degree in 1982 from the National Taiwan University and Ph.D. in biostatistics from UCLA in 1989. He joined MDA in 1991. Dr. Lee’ is active on developing and applying novel biostatistical methods for translational research, particularly in incorporating biomarkers and implementing Bayesian adaptive designs for clinical trials. He is a statistical editor for Journal of the National Cancer Institute and Cancer Prevention Research and an elected Fellow of American Statistical Association.
Professor Chen received his B.S. (1978) and M.S. (1980) degrees from National Taiwan University, and Ph.D. (1986) in Pharmaceutical Biochemistry from University of Wisconsin-Madison. He then worked at University of Wisconsin as a postdoctoral fellow for another year. He started his independent career as Assistant Professor of Pharmaceutical Science at University of Rhode Island in 1987 and became Associate Professor in 1991. He moved to University of Kentucky as Associate Professor in 1995 and was promoted to Professor in 1998. He joined the medicinal chemistry faculty at the Ohio State University Medical Center in 2001, and is the holder of the Lucius A. Wing Chair of Cancer Research and Therapy (2004-present). Since August 2014, he has been Director of Institute of Biological Chemistry at Academia Sinica, and Professor of Medicinal Chemistry at the Ohio State University and Professor of Biochemical Sciences at National Taiwan University.
Professor Chen was a recipient of NIH Shannon Award (1994), The V Foundation-AACR Translational Cancer Research award (2004), Prostate Cancer Foundation (formerly CaP Cure) award (2007, 2008), Hearst Foundation award (2008), and several awards at the Ohio State University, including Kimberly Chair Professorship (2003 – 2006), Innovation in Drug Discovery Award (2008), Inaugural Innovator of the Year Award (2010), and Distinguished University Scholar Award (2010). He is an elected fellow of American Association for the Advancement of Science (2004) and National Academy of Inventors (2014).
His research interest is to develop small-molecule agents to interrogate crosstalk mechanisms between cancer cells and tumor microenvironment in the course of tumor progression. Among a series of targeted therapeutic agents he developed, the PDK-1/Akt inhibitor OSU-03012 (AR-12) and the HDAC inhibitor OSU-HDAC42 (AR-42) have been successfully brought into clinical trials in cancer patients. He is the author and co-author of 245 publications (H-index 57) and 24 patents. His recent work involves the development of novel cancer therapeutic agents that target KRAS signaling, cancer cachexia, cell surface receptor recycling, Notch and Hippo signaling pathways, as well as host-targeted broad-spectrum antiviral agents.
Dr.Lian conducted his undergraduate study in engineering physics and bioengineering, andmentored by Dr.Shu Chien during his graduate study in UCSD. To compliment his training in the engineering field, Dr.Lian receives his postdoc apprenticeship under Dr.Kun-Liang Guan in the area of cancer and stem cell biology. As an independent investigator at Lamar University, Dr.Lian combines basic science and engineering approaches to study the effect of microenvironment on the metastatic potential of cancer cells. In addition, his lab collaborated with teams in UCSD and Rice University to develop an lification free nucleic-acid detection platform for the purpose of early cancer detection.
Chieh-Yuan Li (Alex) graduated from UC Berkeley with a B.S. in Chemical Biology and has several years of experience in biotechnology companies including Life Technologies by Thermo Fisher Scientific and Roche Molecular Diagnostics. As an R&D scientist, he was involved in developing genomic assays and technologies such as single-cell RNA-Seq, targeted-resequencing, gene expression, genotyping qPCR and IVD use assay. Alex is also the author of several patents and inventor of Ion Torrent’s isothermal NGS sample preparation technology. Currently, Alex is pursuing a Ph.D. at the University of Texas MD Anderson Cancer Center.
Diane Tang-Liu is the CEO of DTL BioPharma Consulting, Inc., which provides strategic advice, operational expertise, and consulting services to biotechnology and pharmaceutical companies. Diane has co-founded Allgenesis, Inc. (新源生物科技), which develops NCEs and therapeutic proteins for global markets. She has 30 years of experience in pharmaceutical development with Allergan, Inc., and spent over 20 years in R&D executive and portfolio management.
Dr. Tang-Liu is a full adjunct professor of Pharmacology and Pharmaceutical Sciences at the University of Southern California, and of Bioengineering and Therapeutic Sciences at the University of California, San Francisco. Diane was elected AAPS Fellow and ACCP Fellow.
Diane received B.S. in Pharmacy from National Taiwan University, and Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco.
Dr. Hong’s longstanding interest in improving cancer therapy has led to a series of breakthroughs and a number of patents in drug carrier technology for improving drug and gene delivery. After being a consultant to several biotech companies, Dr. Hong founded Taiwan Liposome Company in Taiwan and its subsidiary, TLC Biopharmaceuticals in United States. He currently serves as Chairman & CEO. Dr. Hong has built a team to pursue the dream of becoming a Taiwanese pharmaceutical company having drugs developed and made in Taiwan for global market. Under his leadership, TLC has been selected by Red Herring as a Winner of Asia Top 100 Company in 2006 and a Finalist of Global Top 100 in 2007.
Dr. Wu was born on a farm on the bank of Jhoushue River (濁水溪) in Nantou County, Taiwan. His education include: BS in Agricultural Chemistry, National Taiwan University (1963); Ph.D. in Biochemistry, University of Wisconsin-Madison (1970); and postdocoral training at Johns Hopkins Medical School and University of Pittsburgh Medical school. He started his academic career at University of Miami Medical School/Howard Hughes Medical Institute and later moved to University of North Texas Health Science Center at Fort Worth until his retirement in 2006. Major roles at medical schools were teaching, research and committee services. He moved back to Taiwan to serve as President/CEO at Development Center for Biotechnology in Taipei. He concluded his service there at the end of 2008, returned to Texas fully retired. His research can be divided into 3 periods. First is the undergraduate, graduate and postdoc period. He was trained in carbohydrate chemistry, then changed from Chemistry to Hematology, working in the area of hematopoietic growth factors (CSFs): structure, function and mechanism of action in hematopoiesis. He has also worked in the area of plasminogen activator (coagulation) and its possible roles in cancer metastasis. Later he developed his interests in stem cells which include bone marrow, cord blood and mesenchymal stem cell studying their potential application in tissue repair and/or replacement. In addition to serving as consultant on several biotech projects, he is also a cofounder of a start-up company, which is in the process of developing a universal pneumonia vaccine.
Dr. Ying-Ja Chen is a Patent Agent at Pronutria Biosciences, a Boston-based biotech startup developing first-in-class oral biologics. Her role at Pronutria Biosciences transitioned from research in discovery science, where she focused on protein engineering, into intellectual property, where she develops strategies and prosecutes patent applications. She holds a BS. In Electrical Engineering from National Taiwan University, a Ph.D. in Bioengineering from the University of California, San Diego working with Dr. Xiaohua Huang on genome sequencing, and completed postdoctoral training at MIT with Dr. Christopher Voigt in synthetic biology.
Dr. Po-Tsan Ku is a Career Development Specialist at the University of Texas at Austin. He counsels graduate students and postdocs in career exploration, job searches and professional development. Before coming to UT Austin, he has been a product marketing manager with over thirteen years of experience in the biotechnology industry, including Ambion, Life Technologies and EMD Millipore. Prior to joining biotech industry, he completed postdoctoral training at UT Austin and Baylor College of Medicine. He received a MBA from UT Austin, PhD in Cell and Developmental Biology from Harvard University, and BS in Biology from University of South Florida.
Dr. Elaine Chan is a bioengineer and scientist by training. She received her bachelor’s degree from Rice University and her Ph.D. from the University of California at San Diego, with a research focus in cartilage tissue engineering and 3-D statistical shape modeling. Her research interests include imaging and analysis of orthopedic medical devices and treatments, and her professional goal is to foster cross-cultural collaborations and assist Asia-based biotech companies to enter the US market. She currently works as a Client Services Manager at Medical Metrics, Inc., an imaging core lab for clinical trials.
Dr. Chuang received her Ph.D. in biomedical sciences from Baylor College of Medicine with a focus on molecular and cellular biology. Prior to joining the Department of Investigational Therapeutics at MD Anderson Cancer Center (MDACC), she was a patent research analyst at Global Patent Solutions and a postdoctoral fellow in the Department of Translational Molecular Pathology at MDACC. Dr. Chuang joined MDACC as a regulatory coordinator in September 2014. Her various experiences have provided her with the tools to efficiently process clinical protocols to meet tight deadlines and to effectively communicate expected timelines and deliverables to the study Sponsor/CRO.